RESCRIPTOR Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Additional details are available on the delavirdine mesylate profile page.

Summary for RESCRIPTOR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	7
Patent Applications:	4,327
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for RESCRIPTOR
DailyMed Link:	RESCRIPTOR at DailyMed

Drug patent expirations by year for RESCRIPTOR

Recent Clinical Trials for RESCRIPTOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Mental Health (NIMH)	Phase 2/Phase 3
University of California, San Diego	Phase 2/Phase 3
National Institutes of Health (NIH)	Phase 2/Phase 3

See all RESCRIPTOR clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for RESCRIPTOR

J05AG	Non-nucleoside reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for RESCRIPTOR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for RESCRIPTOR

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	⤷ Try a Trial	⤷ Try a Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	⤷ Try a Trial	⤷ Try a Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	⤷ Try a Trial	⤷ Try a Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for RESCRIPTOR

See the table below for patents covering RESCRIPTOR around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Hungary	211241		⤷ Try a Trial
New Zealand	508762	Delavirdine tablet formulation	⤷ Try a Trial
Australia	4213499		⤷ Try a Trial
Hungary	T61296		⤷ Try a Trial
Germany	69028552		⤷ Try a Trial
Hong Kong	1036417		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for RESCRIPTOR

Recent Clinical Trials for RESCRIPTOR

Anatomical Therapeutic Chemical (ATC) Classes for RESCRIPTOR

Make Better Decisions: Try a trial or see plans & pricing